Noile-Immune Biotech Inc.
Tokyo Stock Exchange 4893.T
Noile-Immune Biotech Inc. EBT Margin for the year ending December 31, 2023: -355.91%
Noile-Immune Biotech Inc. EBT Margin is -355.91% for the year ending December 31, 2023, a -479.71% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
-
Noile-Immune Biotech Inc. EBT Margin for the year ending December 31, 2022 was -61.40%, a 92.20% change year over year.
-
Noile-Immune Biotech Inc. EBT Margin for the year ending December 31, 2021 was -786.86%, a -21.31% change year over year.
-
Noile-Immune Biotech Inc. EBT Margin for the year ending December 31, 2020 was -648.63%.
Key data
| Date | EBT Margin | Net Income Margin | EBITDA Margin | EBIT Margin |
|---|
Market news
Loading...
Tokyo Stock Exchange: 4893.T
| CEO | Mr. Koji Tamada M.D., Ph.D. |
| IPO Date | June 28, 2023 |
| Location | Japan |
| Headquarters | 2-12-10 |
| Employees | 28 |
| Sector | Health Care |
| Industries | |
Description
Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email